Objective:To compare the efficacy and safety of Novoiaped 30 and NovoMix 30 Flexpen in the therapy of type 2 diabetes mellitus(DM). Methods:A multicenter

randomized

and controlled clinical trial of Novorapid 30R and Novomix 30 Flexpen was performed in XinQiao Hospital in Chongqing China. One hundred and fifty patients with type 2 DM received Novorapid 30R therapy and sixty patients received NovoMix 30 Flexpen for 12 weeks respectively. Results:(1)At the end of 12-week treatment

significant improvements in HbA1C and fasting plasma glucose(FPG) levels were shown in both groups

HbA1C decreased 1.08% and 1.01%

and FPG decreased 2.0mmol/L and 2.2mmol/L

in Novorapid 30R and NovoMix 30 Flexpen group respectively(all P<0.05). But the difference between two groups was of no statistical significance(P>0.05). (2)2hpG decreased 3.79mmol/L and 3.05mmol/L

Novorapid 30R was better than Novomix 30 Flexpen

The difference was statistically significant between two groups(P<0.05). (3)Hypoglycemia incidences were 12% and 14%in Novorapid 30R and Novomix 30 Flexpen respectively

and most events were mild. Conclusion:Novorapid 30R is an effective and safe regimen in treatingdiabetes.